Monday, May 23, 2022 Daily Archives

eBook: Biopharmaceutical Outsourcing — Capacities, Companies, and Current Trends

by

Although many biopharmaceutical companies leverage in-house capabilities to produce their therapies, contract manufacturing partners represent a significant part of the biologics industry. Recent capacity investments, facility expansions, and mergers and acquisitions (M&A) activity even suggest that third-party biologics production is gaining traction. In this eBook, BioProcess Insider’s founding editor, Dan Stanton, takes the pulse of today’s outsourcing sector. First, he speaks with Dawn Ecker (director of bioTRAK database services at BDO) to establish what kinds of companies are amassing mammalian…

May 23, 2022

Keeping supply chains resilient in times of crisis

by

Robust risk management can offset supply chain problems that have been further aggravated by COVID-19, says Samsung Bioepis’ Thomas Newcomer. Since the start of the COVID-19 pandemic, the pharmaceutical industry has experienced many unprecedented situations. Disruptions to drug supply chains has become a primary concern across various markets. As much of the industry’s resources has been invested in pandemic response, the pharmaceutical industry has experienced an increase in supply chain or regulatory bottlenecks and in some cases drug shortages. This…

May 23, 2022

AGC doubles viral vector capacity at Longmont plant

by

AGC Biologics is adding viral vector suspension technology and capacity to advance manufacturing of gene therapies at its Longmont, Colorado facility. The expansion will come online in the third quarter of 2022 to help meet market demands and, according to the contract development manufacturing organization (CDMO), the investment will more than double the site’s viral vector capacity. “Viral vector manufacturing is a complex process and developers are turning to AGC Biologics because we have the expertise and programs to help…

May 23, 2022

MilliporeSigma pumps $470m into Ireland filtration plants

by

Merck Life Science – aka MilliporeSigma – will build facilities to increase filtration equipment and membrane capacity at sites in Cork, Ireland. The total investment is split between two facilities in Cork, with a new filtration manufacturing facility being built at Blarney Business Park for €150 million ($160 million) and €290 million being invested in nearby Carrigtwohill for a manufacturing plant supporting the immersion casting of membranes. From Carrigtwohill, the first commercial products will be produced in 2026. “At full…

May 23, 2022